ACURA PHARMACEUTICALS 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934
July 27, 2012
Date of Report (Date of earliest event reported)
ACURA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
616 N. North Court, Suite 120
Palatine, Illinois 60067
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On July 27, 2012 we issued a press release disclosing that Pfizer Inc. has provided notice of exercise of its right to terminate the license to three development-stage products using the Company’s Aversion® Technology and return such products to us. The termination will become effective in 12 months under our License Agreement with a subsidiary of Pfizer. A fourth product utilizing our Aversion® Technology, OXECTA® (oxycodone hydrochloride) Tablets CII, is being commercialized by Pfizer and Pfizer will retain all rights and obligations relating to OXECTA® under the License Agreement. A copy of our press release is being furnished as Exhibit 99.1 hereto.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: July 27, 2012